Christina Maria Joseph Elisabeth Vandenbroucke-Grauls
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Christina Maria Joseph Elisabeth Vandenbroucke-Grauls has a total of 194 co-authors. Here are the top co-authors by number of shared publications:
- Tessel Meike van Rossen
Department of Medical Microbiology & Infection Control, Amsterdam UMC, Vrije Universiteit Amsterdam
3 shared publications - Alex Koek
Amsterdam UMC, Vrije Universiteit Amsterdam, Medical Microbiology and Infection Control, Amsterdam Immunity and Infection Institute, Amsterdam, The Netherlands
2 shared publications - Alma Becic Pedersen
Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
2 shared publications - Andreas Voss
Department of Medical Microbiology, Radboudumc, 6500 HB Nijmegen, The Netherlands
2 shared publications - Anna Maria Kaiser
Department of Medical Microbiology and Infection Control, VU university medical center, PK 1 X 124, P.O. Box 7057, 1007 MB Amsterdam, the Netherlands
2 shared publications - Diederik van de Beek
Amsterdam UMC
2 shared publications
Latest Publications
- 3 October 2026
- Published by Springer Nature in European Geriatric Medicine
- Vol. 17 (5) , 2869-2880
Interaction between mental health conditions and hip fracture on the 30-day risk of infection among older adults: a Danish matched cohort study
- 3 October 2026
- Published by Springer Nature in European Geriatric Medicine
- Vol. 17 (5) , 2869-2880
Interaction between mental health conditions and hip fracture on the 30-day risk of infection among older adults: a Danish matched cohort study
- Open Access
- 1 February 2025
- Published by Taylor & Francis in Clinical Epidemiology
- Vol. ume 17, 167-176
Interaction Between Multimorbidity and Hip Fracture Surgery Leads to Excess Risk of Infection: A Danish Registry-Based Cohort Study of 92,599 Patients With Hip Fracture
Purpose: Infection in general is a frequent and serious complication after hip fracture (HF) surgery. Multimorbidity in HF patients is associated with elevated infection risk. It remains unclear whether multimorbidity interacts with HF surgery to increase infection risk beyond their individual effects. Methods: Using Danish registries, we identified 92,599 patients ≥ 65 years surgically treated for HF 2004 to 2018 and an age- and sex-matched comparison cohort from the background population without HF (n=462,993). Multimorbidity was defined using the Charlson Comorbidity Index in categories no, moderate, or severe. We computed incidence rates (IR) of any kind of hospital-treated infection within 1 month and 1 year with 95% confidence intervals and estimated the attributable proportion (in %) based on differences in IRs. Results: The IR of infection within 1 month was 181 (176– 186) per 100 person years in HF patients with no multimorbidity and 9 (95% CI 8– 9) in the comparison cohort with no multimorbidity. The IRs were 240 (234– 246) and 302 (291– 313) in HF patients with moderate and severe multimorbidity compared with 17 (16– 18) and 31 (30– 33) in the comparison cohort with same multimorbidity level. The attributable proportion indicates that 21% and 33% of the IR among HF patients with moderate and severe multimorbidity, respectively, was explained by interaction. Similar interactions were observed within 1 year. Conclusion: Multimorbidity and HF surgery interact synergistically, which substantially increases the infection risk. The interaction effect increased with multimorbidity level. Our findings highlight the potential benefits of implementing more targeted and personalized preventive initiatives for multimorbid patients.
- 1 February 2025
- Published by Taylor & Francis in Clinical Epidemiology
- Vol. ume 17, 167-176
Open AccessInteraction Between Multimorbidity and Hip Fracture Surgery Leads to Excess Risk of Infection: A Danish Registry-Based Cohort Study of 92,599 Patients With Hip Fracture
Purpose: Infection in general is a frequent and serious complication after hip fracture (HF) surgery. Multimorbidity in HF patients is associated with elevated infection risk. It remains unclear whether multimorbidity interacts with HF surgery to increase infection risk beyond their individual effects. Methods: Using Danish registries, we identified 92,599 patients ≥ 65 years surgically treated for HF 2004 to 2018 and an age- and sex-matched comparison cohort from the background population without HF (n=462,993). Multimorbidity was defined using the Charlson Comorbidity Index in categories no, moderate, or severe. We computed incidence rates (IR) of any kind of hospital-treated infection within 1 month and 1 year with 95% confidence intervals and estimated the attributable proportion (in %) based on differences in IRs. Results: The IR of infection within 1 month was 181 (176– 186) per 100 person years in HF patients with no multimorbidity and 9 (95% CI 8– 9) in the comparison cohort with no multimorbidity. The IRs were 240 (234– 246) and 302 (291– 313) in HF patients with moderate and severe multimorbidity compared with 17 (16– 18) and 31 (30– 33) in the comparison cohort with same multimorbidity level. The attributable proportion indicates that 21% and 33% of the IR among HF patients with moderate and severe multimorbidity, respectively, was explained by interaction. Similar interactions were observed within 1 year. Conclusion: Multimorbidity and HF surgery interact synergistically, which substantially increases the infection risk. The interaction effect increased with multimorbidity level. Our findings highlight the potential benefits of implementing more targeted and personalized preventive initiatives for multimorbid patients.
- Open Access
- 14 February 2023
- Published by Elsevier in Current Biology
- Vol. 33 (5) , 940-956.e10
CSF-contacting neurons respond to Streptococcus pneumoniae and promote host survival during central nervous system infection
- 14 February 2023
- Published by Elsevier in Current Biology
- Vol. 33 (5) , 940-956.e10
Open AccessCSF-contacting neurons respond to Streptococcus pneumoniae and promote host survival during central nervous system infection
- Top Cited Papers
- 30 January 2023
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 23 (6) , 719-731
Incidence of infection with multidrug-resistant Gram-negative bacteria and vancomycin-resistant enterococci in carriers: a systematic review and meta-regression analysis
- 30 January 2023
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 23 (6) , 719-731
Top Cited PapersIncidence of infection with multidrug-resistant Gram-negative bacteria and vancomycin-resistant enterococci in carriers: a systematic review and meta-regression analysis
- 22 March 2022
- Published by Springer Nature in Nature Medicine
- Vol. 28 (4) , 638-640
Tracing the origins of antibiotic resistance
- 22 March 2022
- Published by Springer Nature in Nature Medicine
- Vol. 28 (4) , 638-640
Tracing the origins of antibiotic resistance
- Open Access
Pneumolysin promotes host cell necroptosis and bacterial competence during pneumococcal meningitis as shown by whole animal dual RNA-seq
SUMMARY: Pneumolysin is a major virulence factor of Streptococcus pneumoniae that plays a key role in interaction with the host during invasive disease. How pneumolysin influences these dynamics between host and pathogen interaction during early phase of central nervous system infection in pneumococcal meningitis remains unclear. Using a whole animal in vivo dual RNA-seq approach, we identified pneumolysin-specific transcriptional responses in both S. pneumoniae and zebrafish ( Danio rerio ) during early pneumococcal meningitis. By functional enrichment analysis we identified host pathways known to be activated by pneumolysin, and discovered the importance of necroptosis for host survival. Inhibition of this pathway using the drugs necrostatin-5 or GSK’872 increased host mortality during pneumococcal meningitis. On the pathogen’s side, we find that pneumolysin-dependent competence activation is crucial for intra-host replication and virulence and that not all bacteria activate competence at the same time. Altogether, this study provides new insights into pneumolysin-specific transcriptional responses and identifies key pathways involved in pneumococcal meningitis. GRAPHICAL HIGHLIGHTS: Pneumolysin-specific host and bacterial responses as identified by whole animal dual RNA-seq, available at https://veeninglab.com/dual-danio Discovery of a functional necroptosis or necroptosis-like pathway in zebrafish Heterogeneity in competence development during infection Competence development is an important virulence determinant
Open AccessPneumolysin promotes host cell necroptosis and bacterial competence during pneumococcal meningitis as shown by whole animal dual RNA-seq
SUMMARY: Pneumolysin is a major virulence factor of Streptococcus pneumoniae that plays a key role in interaction with the host during invasive disease. How pneumolysin influences these dynamics between host and pathogen interaction during early phase of central nervous system infection in pneumococcal meningitis remains unclear. Using a whole animal in vivo dual RNA-seq approach, we identified pneumolysin-specific transcriptional responses in both S. pneumoniae and zebrafish ( Danio rerio ) during early pneumococcal meningitis. By functional enrichment analysis we identified host pathways known to be activated by pneumolysin, and discovered the importance of necroptosis for host survival. Inhibition of this pathway using the drugs necrostatin-5 or GSK’872 increased host mortality during pneumococcal meningitis. On the pathogen’s side, we find that pneumolysin-dependent competence activation is crucial for intra-host replication and virulence and that not all bacteria activate competence at the same time. Altogether, this study provides new insights into pneumolysin-specific transcriptional responses and identifies key pathways involved in pneumococcal meningitis. GRAPHICAL HIGHLIGHTS: Pneumolysin-specific host and bacterial responses as identified by whole animal dual RNA-seq, available at https://veeninglab.com/dual-danio Discovery of a functional necroptosis or necroptosis-like pathway in zebrafish Heterogeneity in competence development during infection Competence development is an important virulence determinant
- Open Access
- 11 November 2021
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 35 (8)
Esophageal microbiota composition and outcome of esophageal cancer treatment: a systematic review
Background: The role of esophageal microbiota in esophageal cancer treatment is gaining renewed interest, largely driven by novel DNA-based microbiota analysis techniques. The aim of this systematic review is to provide an overview of current literature on the possible association between esophageal microbiota and outcome of esophageal cancer treatment, including tumor response to (neo)adjuvant chemo(radio)therapy, short-term surgery-related complications, and long-term oncological outcome. Methods: A systematic review of literature was performed, bibliographic databases were searched and relevant articles were selected by two independent researchers. The Newcastle-Ottawa scale was used to estimate the quality of included studies. Results: The search yielded 1303 articles, after selection and cross-referencing, five articles were included for qualitative synthesis and four studies were considered of good quality. Two articles addressed tumor response to neoadjuvant chemotherapy and described a correlation between high intratumoral Fusobacterium nucleatum levels and a poor response. One study assessed surgery-related complications, in which no direct association between esophageal microbiota and occurrence of complications was observed. Three studies described a correlation between shortened survival and high levels of intratumoral F. nucleatum, a low abundance of Proteobacteria and high abundances of Prevotella and Streptococcus species. Conclusions: Current evidence points towards an association between esophageal microbiota and outcome of esophageal cancer treatment and justifies further research. Whether screening of the individual esophageal microbiota can be used to identify and select patients with a predisposition for adverse outcome needs to be further investigated. This could lead to the development of microbiota-based interventions to optimize esophageal microbiota composition, thereby improving outcome of patients with esophageal cancer.
- 11 November 2021
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 35 (8)
Open AccessEsophageal microbiota composition and outcome of esophageal cancer treatment: a systematic review
Background: The role of esophageal microbiota in esophageal cancer treatment is gaining renewed interest, largely driven by novel DNA-based microbiota analysis techniques. The aim of this systematic review is to provide an overview of current literature on the possible association between esophageal microbiota and outcome of esophageal cancer treatment, including tumor response to (neo)adjuvant chemo(radio)therapy, short-term surgery-related complications, and long-term oncological outcome. Methods: A systematic review of literature was performed, bibliographic databases were searched and relevant articles were selected by two independent researchers. The Newcastle-Ottawa scale was used to estimate the quality of included studies. Results: The search yielded 1303 articles, after selection and cross-referencing, five articles were included for qualitative synthesis and four studies were considered of good quality. Two articles addressed tumor response to neoadjuvant chemotherapy and described a correlation between high intratumoral Fusobacterium nucleatum levels and a poor response. One study assessed surgery-related complications, in which no direct association between esophageal microbiota and occurrence of complications was observed. Three studies described a correlation between shortened survival and high levels of intratumoral F. nucleatum, a low abundance of Proteobacteria and high abundances of Prevotella and Streptococcus species. Conclusions: Current evidence points towards an association between esophageal microbiota and outcome of esophageal cancer treatment and justifies further research. Whether screening of the individual esophageal microbiota can be used to identify and select patients with a predisposition for adverse outcome needs to be further investigated. This could lead to the development of microbiota-based interventions to optimize esophageal microbiota composition, thereby improving outcome of patients with esophageal cancer.
- Open Access
GRADING prognostic factors for severe and recurrent Clostridioides difficile infection: expected and unexpected findings. A systematic review
Background: Clostridioides difficile infection (CDI), its subsequent recurrences (rCDI), and severe CDI (sCDI) provide a significant burden for both patients and the healthcare system. Treatment consists of oral antibiotics. Fidaxomicin, bezlotoxumab and fecal microbiota transplantion (FMT) reduce the number of recurrences compared to vancomycin, but are more costly. Identifying patients diagnosed with initial CDI who are at increased risk of developing sCDI/rCDI could lead to more cost-effective therapeutic choices. Objectives: In this systematic review we aimed to identify clinical prognostic factors associated with an increased risk of developing sCDI or rCDI. Methods: PubMed, Embase, Emcare, Web of Science and COCHRANE Library databases were searched from database inception through March, 2021. Study selection was performed by two independent reviewers on the basis of predefined selection criteria; conflicts were resolved by consensus. Cohort and case-control studies providing an analysis of clinical or laboratory data to predict sCDI/rCDI in patients ≥18 years diagnosed with CDI, were included. Risk of bias was assessed with the Quality in Prognostic Research (QUIPS) tool and the quality of evidence by the Grading of Recommendations Assessment, Development and Evaluation (GRADE) tool, modified for prognostic studies. Overview tables of prognostic factors were constructed to assess the number of studies and the respective direction of an association (positive, negative, or no association). Results and conclusions: 136 studies were included for final analysis. Higher age and the presence of multiple comorbidities were prognostic factors for sCDI. Identified risk factors for rCDI were higher age, healthcare-associated CDI, prior hospitalization, PPIs started during/after CDI diagnosis and previous rCDI. Some variables that were found as risk factors for sCDI/rCDI in previous reviews were not confirmed in the current review, which can be attributed to differences in methodology. Risk stratification for sCDI/rCDI may contribute to a more personalized and optimal treatment for patients with CDI.
Open AccessGRADING prognostic factors for severe and recurrent Clostridioides difficile infection: expected and unexpected findings. A systematic review
Background: Clostridioides difficile infection (CDI), its subsequent recurrences (rCDI), and severe CDI (sCDI) provide a significant burden for both patients and the healthcare system. Treatment consists of oral antibiotics. Fidaxomicin, bezlotoxumab and fecal microbiota transplantion (FMT) reduce the number of recurrences compared to vancomycin, but are more costly. Identifying patients diagnosed with initial CDI who are at increased risk of developing sCDI/rCDI could lead to more cost-effective therapeutic choices. Objectives: In this systematic review we aimed to identify clinical prognostic factors associated with an increased risk of developing sCDI or rCDI. Methods: PubMed, Embase, Emcare, Web of Science and COCHRANE Library databases were searched from database inception through March, 2021. Study selection was performed by two independent reviewers on the basis of predefined selection criteria; conflicts were resolved by consensus. Cohort and case-control studies providing an analysis of clinical or laboratory data to predict sCDI/rCDI in patients ≥18 years diagnosed with CDI, were included. Risk of bias was assessed with the Quality in Prognostic Research (QUIPS) tool and the quality of evidence by the Grading of Recommendations Assessment, Development and Evaluation (GRADE) tool, modified for prognostic studies. Overview tables of prognostic factors were constructed to assess the number of studies and the respective direction of an association (positive, negative, or no association). Results and conclusions: 136 studies were included for final analysis. Higher age and the presence of multiple comorbidities were prognostic factors for sCDI. Identified risk factors for rCDI were higher age, healthcare-associated CDI, prior hospitalization, PPIs started during/after CDI diagnosis and previous rCDI. Some variables that were found as risk factors for sCDI/rCDI in previous reviews were not confirmed in the current review, which can be attributed to differences in methodology. Risk stratification for sCDI/rCDI may contribute to a more personalized and optimal treatment for patients with CDI.
- Open Access
- 9 January 2021
- Published by SAGE Publications in Therapeutic Advances in Gastroenterology
- Vol. 14
External validation of two prediction tools for patients at risk for recurrent Clostridioides difficile infection
One in four patients with primary Clostridioides difficile infection (CDI) develops recurrent CDI (rCDI). With every recurrence, the chance of a subsequent CDI episode increases. Early identification of patients at risk for rCDI might help doctors to guide treatment. The aim of this study was to externally validate published clinical prediction tools for rCDI. The validation cohort consisted of 129 patients, diagnosed with CDI between 2018 and 2020. rCDI risk scores were calculated for each individual patient in the validation cohort using the scoring tools described in the derivation studies. Per score value, we compared the average predicted risk of rCDI with the observed number of rCDI cases. Discrimination was assessed by calculating the area under the receiver operating characteristic curve (AUC). Two prediction tools were selected for validation (Cobo 2018 and Larrainzar-Coghen 2016). The two derivation studies used different definitions for rCDI. Using Cobo’s definition, rCDI occurred in 34 patients (26%) of the validation cohort: using the definition of Larrainzar-Coghen, we observed 19 recurrences (15%). The performance of both prediction tools was poor when applied to our validation cohort. The estimated AUC was 0.43 [95% confidence interval (CI); 0.32–0.54] for Cobo’s tool and 0.42 (95% CI; 0.28–0.56) for Larrainzar-Coghen’s tool. Performance of both prediction tools was disappointing in the external validation cohort. Currently identified clinical risk factors may not be sufficient for accurate prediction of rCDI.
- 9 January 2021
- Published by SAGE Publications in Therapeutic Advances in Gastroenterology
- Vol. 14
Open AccessExternal validation of two prediction tools for patients at risk for recurrent Clostridioides difficile infection
One in four patients with primary Clostridioides difficile infection (CDI) develops recurrent CDI (rCDI). With every recurrence, the chance of a subsequent CDI episode increases. Early identification of patients at risk for rCDI might help doctors to guide treatment. The aim of this study was to externally validate published clinical prediction tools for rCDI. The validation cohort consisted of 129 patients, diagnosed with CDI between 2018 and 2020. rCDI risk scores were calculated for each individual patient in the validation cohort using the scoring tools described in the derivation studies. Per score value, we compared the average predicted risk of rCDI with the observed number of rCDI cases. Discrimination was assessed by calculating the area under the receiver operating characteristic curve (AUC). Two prediction tools were selected for validation (Cobo 2018 and Larrainzar-Coghen 2016). The two derivation studies used different definitions for rCDI. Using Cobo’s definition, rCDI occurred in 34 patients (26%) of the validation cohort: using the definition of Larrainzar-Coghen, we observed 19 recurrences (15%). The performance of both prediction tools was poor when applied to our validation cohort. The estimated AUC was 0.43 [95% confidence interval (CI); 0.32–0.54] for Cobo’s tool and 0.42 (95% CI; 0.28–0.56) for Larrainzar-Coghen’s tool. Performance of both prediction tools was disappointing in the external validation cohort. Currently identified clinical risk factors may not be sufficient for accurate prediction of rCDI.
- Open Access
- 3 June 2020
- Published by Cold Spring Harbor Laboratory in medRxiv
Is death from Covid-19 a multistep process?
Covid-19 death has a different relationship with age than is the case for other severe respiratory pathogens. The Covid-19 death rate increases exponentially with age, and the main risk factors are age itself, as well as having underlying conditions such as hypertension, diabetes, cardiovascular disease, severe chronic respiratory disease and cancer. Furthermore, the almost complete lack of deaths in children suggests that infection alone is not sufficient to cause death; rather, one must have gone through a number of changes, either as a result of undefined aspects of aging, or as a result of chronic disease. These characteristics of Covid-19 death are consistent with the multistep model of disease, a model which has primarily been used for cancer, and more recently for amyotrophic lateral sclerosis (ALS). We applied the multi-step model to data on Covid-19 case fatality rates (CFRs) from China, South Korea, Italy, Spain and Japan. In all countries we found that a plot of ln (CFR) against ln (age) was approximately linear with a slope of about 5. As a comparison, we also conducted similar analyses for selected other respiratory diseases. SARS showed a similar log-log age-pattern to that of Covid-19, albeit with a lower slope, whereas seasonal and pandemic influenza showed quite different age-patterns. Thus, death from Covid-19 and SARS appears to follow a distinct age-pattern, consistent with a multistep model of disease that in the case of Covid-19 is probably defined by comorbidities and age producing immune-related susceptibility. Identification of these steps would be potentially important for prevention and therapy for SARS-COV-2 infection.
- 3 June 2020
- Published by Cold Spring Harbor Laboratory in medRxiv
Open AccessIs death from Covid-19 a multistep process?
Covid-19 death has a different relationship with age than is the case for other severe respiratory pathogens. The Covid-19 death rate increases exponentially with age, and the main risk factors are age itself, as well as having underlying conditions such as hypertension, diabetes, cardiovascular disease, severe chronic respiratory disease and cancer. Furthermore, the almost complete lack of deaths in children suggests that infection alone is not sufficient to cause death; rather, one must have gone through a number of changes, either as a result of undefined aspects of aging, or as a result of chronic disease. These characteristics of Covid-19 death are consistent with the multistep model of disease, a model which has primarily been used for cancer, and more recently for amyotrophic lateral sclerosis (ALS). We applied the multi-step model to data on Covid-19 case fatality rates (CFRs) from China, South Korea, Italy, Spain and Japan. In all countries we found that a plot of ln (CFR) against ln (age) was approximately linear with a slope of about 5. As a comparison, we also conducted similar analyses for selected other respiratory diseases. SARS showed a similar log-log age-pattern to that of Covid-19, albeit with a lower slope, whereas seasonal and pandemic influenza showed quite different age-patterns. Thus, death from Covid-19 and SARS appears to follow a distinct age-pattern, consistent with a multistep model of disease that in the case of Covid-19 is probably defined by comorbidities and age producing immune-related susceptibility. Identification of these steps would be potentially important for prevention and therapy for SARS-COV-2 infection.